Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Germany.
J Hypertens. 2011 Feb;29(2):266-72. doi: 10.1097/HJH.0b013e328340aa72.
Spontaneously hypertensive rats (SHRs) are characterized by capillary rarefaction, which may contribute to blood pressure elevation. We hypothesized that capillary rarefaction involves a suppressed angiogenesis; renin inhibition influences anti-angiogenesis homeostasis by acting on angiopoietins; transient renin blockade reduces anti-angiogenesis thereby ameliorating long-lasting blood pressure and cardiac hypertrophy in SHRs.
First, serum angiopoietin-1 and angiopoietin-2 were measured in 2-month old normotensive Wistar-Kyoto rats (WKYs) and SHRs after renin inhibition (aliskiren: 1 and 10 mg/kg per day) or placebo. Second, 4-week old SHRs were prehypertensively treated with aliskiren (1 and 10 mg/kg per day) or placebo for 4 weeks. After 4 weeks of 'drug holiday' 12-week old SHRs were given L-nitro-arginine methyl ester (L-NAME) (25 mg/kg per day) for a 4-week interval to promote capillary rarefaction. Thereafter, mean arterial pressure (MAP), cardiac remodeling, capillary density, pAkt/Akt as marker for cellular survival, pro-angiogenic genes and systemic angiopoietins were investigated.
Baseline angiopoietin levels were similar between WKYs and SHRs. Renin inhibition increased angiopoietin-1 in SHR and reduced angiopoietin-2 in both WKY and SHR blood pressure independently. Prehypertensive renin inhibition reduced MAP and cardiac hypertrophy in adult SHRs. This was associated with higher cardiac capillary density, pAkt/Akt, pro-angiogenic expression pattern and serum angiopoietin-1, whereas angiopoietin-2 was lower as compared to vehicle-pretreated SHRs. These results were independent of prehypertensive blood pressure lowering by aliskiren.
We conclude that renin inhibition modulates anti-angiogenesis signaling independently of blood pressure by increasing angiopoietin-1/angiopoietin-2 ratio. This promotes in SHR stabilization of endothelial cells, favors pro-angiogenic action and consequently results in higher capillary density.
自发性高血压大鼠(SHR)的特征是毛细血管稀疏,这可能导致血压升高。我们假设毛细血管稀疏涉及血管生成抑制;肾素抑制通过作用于血管生成素影响抗血管生成稳态;短暂的肾素阻断减少抗血管生成,从而改善 SHR 的长期血压和心脏肥厚。
首先,在 2 个月大的正常血压 Wistar-Kyoto 大鼠(WKY)和 SHR 中测量血清血管生成素-1 和血管生成素-2,然后进行肾素抑制(阿利克仑:每天 1 和 10mg/kg)或安慰剂处理。其次,4 周龄 SHR 接受阿利克仑(每天 1 和 10mg/kg)或安慰剂预处理 4 周。在 4 周的“停药期”后,12 周龄 SHR 给予 L-硝基精氨酸甲酯(L-NAME)(每天 25mg/kg)4 周,以促进毛细血管稀疏。此后,测量平均动脉压(MAP)、心脏重构、毛细血管密度、pAkt/Akt 作为细胞存活标志物、促血管生成基因和系统血管生成素。
WKY 和 SHR 之间的基线血管生成素水平相似。肾素抑制增加了 SHR 的血管生成素-1,并独立降低了 WKY 和 SHR 血压中的血管生成素-2。预高血压肾素抑制降低了成年 SHR 的 MAP 和心脏肥厚。这与更高的心脏毛细血管密度、pAkt/Akt、促血管生成表达模式和血清血管生成素-1 相关,而血管生成素-2 则低于预先接受药物治疗的 SHR。这些结果与阿利克仑的预降压作用无关。
我们的结论是,肾素抑制通过增加血管生成素-1/血管生成素-2 比值来调节抗血管生成信号,独立于血压。这促进了 SHR 内皮细胞的稳定,有利于促血管生成作用,从而导致更高的毛细血管密度。